Financial Performance - Revenues for Q1 2025 were $401 thousand, a decrease of $701 thousand or 63.6% compared to $1,102 thousand in Q1 2024[100] - Gross profit for Q1 2025 was $196 thousand, down $241 thousand or 55.1% from $437 thousand in Q1 2024, with a profit margin increase to 48.9%[101] - The net loss for Q1 2025 was $2,076 thousand, an increase of $968 thousand or 87.4% compared to a net loss of $1,108 thousand in Q1 2024[100] Expenses - Research and development expenses increased by $166 thousand or 59.1% in Q1 2025, primarily due to higher product development costs[103] - General and administrative expenses rose by $598 thousand or 42.5% in Q1 2025, largely due to increased legal fees related to regulatory inquiries[104] Cash Flow and Capital - Cash and cash equivalents decreased by $1,169 thousand to $12,866 thousand as of March 31, 2025, primarily due to the net loss[106] - Working capital as of March 31, 2025, was $11,099 thousand, down from $12,809 thousand at the end of 2024[107] - Operating activities for Q1 2025 resulted in cash outflows of $1,111 thousand, primarily due to the net loss of $2,076 thousand[108] - Financing activities for the three months ended March 31, 2025, resulted in cash outflows of $17 thousand, primarily due to $41 thousand in tax disbursements for employee restricted stock units, partially offset by $24 thousand in net proceeds from warrant exercises[111] - The company has raised approximately $105.3 million in gross proceeds through equity securities since inception, with ongoing needs for additional capital[86] Compliance and Regulatory Issues - The company received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share, with a compliance period until September 29, 2025[94][95] - The company is at risk of delisting from Nasdaq if it fails to comply with the minimum closing bid price requirement of $1.00 per share by September 29, 2025[122] - The company has been granted 180 calendar days to regain compliance with Nasdaq's listing requirements[123] Internal Controls and Legal Matters - As of March 31, 2025, the company maintained effective disclosure controls and procedures at a reasonable assurance level[115] - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2025, that materially affected internal controls[116] - The management does not expect that the disclosure controls and procedures will prevent or detect all errors and fraud due to inherent limitations[118] - The company is currently not aware of any legal proceedings that may materially affect its business or financial condition[120] - The company is subject to risks associated with proxy contests and actions from activist stockholders, which could interfere with its business plan[124] Stock Issuance - On March 31, 2025, the company issued 3,750 shares of common stock at a fair market value of $0.94 per share from its 2013 Consultant Stock Plan[127] Off-Balance Sheet Transactions - There were no off-balance sheet transactions reported[112]
ClearSign Technologies (CLIR) - 2025 Q1 - Quarterly Report